Top

Cancer Chemotherapy and Pharmacology

Published in:

01-01-2008 | Original Article

Phase II clinical study of gemcitabine in the treatment of patients with advanced nasopharyngeal carcinoma after the failure of platinum-based chemotherapy

Authors: Li Zhang, Yang Zhang, Pei-Yu Huang, Fei Xu, Pei-Jian Peng, Zhong-Zhen Guan

Published in: Cancer Chemotherapy and Pharmacology | Issue 1/2008

Abstract

Purpose

This study was designed to evaluate the anti-tumor activity and toxicity profile of gemcitabine in the treatment of patients with advanced nasopharyngeal carcinoma (NPC) who had been pretreated with platinum-based chemotherapy.

Method

This is an open label, single arm phase II trial. All patients were treated with single agent of gemcitabine. Gemcitabine was given in the dosage of 1.0 g/m² on days 1, 8, 15, each cycle repeated every 4 weeks. Gemcitabine was added to 100 ml normal saline infused over 30 min.

Result

About 32 patients were enrolled in this trial. Thirty patients were assessable for response to treatment. Fourteen patients had a partial response (PR), giving an overall response rate of 43.8% (14/32); 9 patients had stable disease (28.1%) and 7 progressed disease (21.9%). The median time to progression was 5.1 months and median survival time was 16 months, 1 year survival rate was 67%, 2 year overall survival rate was 12%. A total of 11 patients (34.4%) experienced grade 3 and 4 toxicity and the main toxicity was myelosuppression. the non-hematology toxicity was minimal.

Conclusion

The effectiveness of gemcitabine was higher and side effects were minimal in advanced NPC patients after platinum-based chemotherapy failed.

Tang C-Y (1993) Modern oncology. Shanghai University of medical science, Shanghai, pp 586–610

Zhou JC (1998) Practical medical oncology. People’s Health Publisher, Beijing, pp 508–513

Barton-Burke M (1999) Gemcitabine: a pharmacologic and clinical overview (review). Cancer Nurs 22:176–183PubMedCrossRef

Zhang L, Zhang Y, Guan ZZ (2004) Phase II clinical study of gemcitabine single agent for patients with advanced nasopharyngeal carcinoma (NPC) who failed to first line platinum-based chemotherapy. Proc Am Soc Clin Oncol 23:5612a

Green S, Weiss G (1992) Southwest oncology group standard response criteria, endpoint definitions and toxicity criteria. Invest New Drugs 10:239–253PubMedCrossRef

Chan AT, Teo PM, Leuang TW et al (1998) The role of chemotherapy in the management of nasopharyngeal carcinoma. Cancer 82(6):1003–1012PubMedCrossRef

Zhang L, Jiang WQ, Xu RH et al (2000) Clinical study of paclitaxel in the treatment of nasopharyngeal carcinoma. Chin J Cancer 19(8):811–813

Chang JT, Ko JY, Hong RL (2004) Recent advances in the treatment of nasopharyngeal carcinoma. J Formos Med Assoc 103(7):496–510PubMed

Poon D, Chowbay B, Leong SS et al (2004) Singapore phase II study of irinotecan (CPT-11) as salvage therapy for advanced nasopharyngeal carcinoma (NPC). ASCO Ab5576

10.

Foo KF, Tan EH, Leong SS et al (2002) Gemcitabine in metastatic nasopharyngeal carcinoma of the undifferentiated type. Ann Oncol 13:150–156PubMedCrossRef

11.

Ma BB, Tannock IF, Pond GR et al (2002) Chemotherapy with gemcitabine-containing regimens for locally recurrent or metastatic nasopharyngeal carcinoma. Cancer 95:2516–2523PubMedCrossRef

12.

Ngan RKC, Yiu HHY, Lau WH, Yau S et al (2002) Combination gemcitabine and cisplatin chemotherapy for metastatic or recurrent nasopharyngeal carcinoma. Ann Oncol 13:1252–1258PubMedCrossRef

Title: Phase II clinical study of gemcitabine in the treatment of patients with advanced nasopharyngeal carcinoma after the failure of platinum-based chemotherapy
Authors: Li Zhang
Yang Zhang
Pei-Yu Huang
Fei Xu
Pei-Jian Peng
Zhong-Zhen Guan
Publication date: 01-01-2008
Publisher: Springer-Verlag
Published in: Cancer Chemotherapy and Pharmacology / Issue 1/2008
Print ISSN: 0344-5704
Electronic ISSN: 1432-0843
DOI: https://doi.org/10.1007/s00280-007-0441-8

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Purpose

Method

Result

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2008

Capecitabine and doxorubicin combination chemotherapy as salvage therapy in pretreated advanced gastric cancer

Comparison of pharmacokinetic and metabolic profiling among gossypol, apogossypol and apogossypol hexaacetate

Phase II trial of gemcitabine combined with cisplatin in patients with inoperable biliary tract carcinomas

Pharmacometrics and delivery of novel nanoformulated PEG-b-poly(ε-caprolactone) micelles of rapamycin

The combination of capecitabine and irinotecan in treating 5-Fluorouracil- and Oxaliplatin-pretreated metastatic colorectal cancer

Pharmacokinetics of oxaliplatin in patients with severe hepatic dysfunction

Keynote webinar | Spotlight on antibody–drug conjugates in cancer